Equillium Inc (EQ)
1.51
+0.05
(+3.42%)
USD |
NASDAQ |
May 02, 15:02
Equillium Cash from Financing (Quarterly): 0.079M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.079M |
| September 30, 2023 | -0.26M |
| June 30, 2023 | -7.618M |
| March 31, 2023 | -1.429M |
| December 31, 2022 | -1.356M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.141M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.225M |
| September 30, 2021 | 0.174M |
| June 30, 2021 | 0.698M |
| March 31, 2021 | 29.96M |
| Date | Value |
|---|---|
| December 31, 2020 | 0.011M |
| September 30, 2020 | 53.06M |
| June 30, 2020 | 0.096M |
| March 31, 2020 | 0.775M |
| December 31, 2019 | -0.105M |
| September 30, 2019 | 9.941M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 64.76M |
| September 30, 2018 | 0.001M |
| June 30, 2018 | 1.602M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-7.618M
Minimum
Jun 2023
53.06M
Maximum
Sep 2020
4.442M
Average
0.079M
Median
Dec 2023
Cash from Financing (Quarterly) Benchmarks
| Janux Therapeutics Inc | 0.831M |
| Retractable Technologies Inc | -0.1364M |
| Mersana Therapeutics Inc | 0.092M |
| Spero Therapeutics Inc | 0.001M |
| Vera Therapeutics Inc | 24.83M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.664M |
| Cash from Investing (Quarterly) | -5.566M |
| Free Cash Flow | -21.83M |
| Free Cash Flow Per Share (Quarterly) | -0.1621 |
| Free Cash Flow to Equity (Quarterly) | -5.699M |
| Free Cash Flow to Firm (Quarterly) | -5.699M |
| Free Cash Flow Yield | -41.64% |